Protocol version for countries where patients treated off-label cannot be included in the disease registry: A Post-Authorisation Disease Registry Safety Study to Generate Data on the Long-Term Safety and Clinical Effectiveness of SCENESSE® (Afamelanotide 16mg) in Patients with Erythropoietic Protoporphyria (EPP). (SCENESSE® PASS-002)